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Summary.-Sera from 57 patients with malignant melanoma and 39 control patients
were tested by immunofluorescence techniques against 6 melanoma cell lines.
Thirty-two per cent of tests with sera from melanoma patients showed fluorescence
with these cell lines whereas only 1700 of tests with control sera were positive.
Reactions occurred in 210o of tests with sera from patients with primary melanoma
compared with 4000 with secondary melanomata and 5400 with " cured " melano-
mata. The cell lines varied in antigenicity but this did not correlate with either
pigmentation or length of time in culture. The cell lines which were most reactive
with sera from melanoma patients were also most reactive with control sera.
MALIGNANT melanoma has long been
considered to be one ofthe more immuno-
genic human tumours. Studies bv Lewis
(1967), and subsequently by a number
ofworkers using immunofluorescence tech-
niques, seem to have substantiated that
view by demonstrating antibody to
melanoma cells in the serum of melanoma
patients (Morton et al., 1968; Oettgen et
al., 1968; Muna, Marcus and Scott,
1969; Lewis et al., 1969; Rohmsdahl and
Cox, 1970).
Four of these 5 groups of workers
described antibody to melanoma cells in
the sera of approximately 60% of melan-
oma patients and in 1020% of control
sera. WAhile similar final results have
been obtained there have been marked
differences in techniques, antibody titres
obtained and even in the intracellular
location ofthe fluorescence.
This report describes a study of sera
from 57 melanoma patients with varying
degrees of tumour spread and 39 normal
sera using immunofluorescent techniques
with 6 melanoma cell lines.
MATERIALS AND METHODS
The cell lines used were all derived from
secondarv melanomata, either subcutaneous
deposits or metastatic lymph nodes. Four
of the cell lines (M1M96, MM127, MiM138 and
MiM170) have been described in detail else-
where (Whitehead and Little, 1972). The
other 2 cell lines (MM181 and M1M82) were
used at early passage levels and have not
been studied in depth. Details of the cell
lines used are given in Table I.
TABLE L.-Detai!s ofMelanoma Cell
Lines U-sed
Designation
MM 96
M 127
MM 138
1M 170
MM 181
fM 182
Oi&n Pigmi
Ly-mph node
Nodule
Nodule
Lymph node
Nodule
Lymph node
Passage
entation level
+ 40-60
- 20-30
+ 20-30
-+ 15-20
- < 10
- < 10
The cells grew as monolayers and were
removed by scraping or by treatment with
versene (0.02%). The cells were suspended
in RPM1 1640 + 2% foetal calf serum and
were dropped on to acid cleaned slides and
allowed to air dry. The smears were fixed
either in cold acetone for 20 min or in liquid
nitrogen-isopentane (Lewis et al., 1969) and
again air dried before use. Cells from
apparently normal fibroblast cultures ob-
tained from primary melanoma cultures, or
from foetal skin, were treated in the same
way and used as controls.R. H. WHITEHEAD
Sera were obtained from melanoma
patients on the day of operation. Thirty-
nine control sera were obtained from labora-
tory staff, patients having naevi or warts
removed and in the case of the New Guinea
sera. were from an Epstein-Barr virus study
(J. H. Pope, personal communication). For
the purpose of this study patients were
considered as cured" if they were tumour
free 3 years or more after tumour removal.
Where possible, the primary melanomata
were classified bv one pathologist according
to the criteria of Clark (1967) and J. H.
Little (personal communication). However,
a few sera from melanoma patients were
received from other sources and in these
cases the patient's tumour was not classified
in this way.
Sera were stored at -20'C and diluted
1/6 for use. Sera were incubated with
smears of the cells at room temperature for
30 min. The smears were washed 3 times
in phosphate buffered saline (pH 7.2) and
incubated with FITC-conjugated antihuman
gamma globulin (Baltimore Biological Labor-
atories, Marvland) for 30 min at room
temperature. After washing again. the
smears were partially dried and mounted in
a drop of 90% glycerol (pH 8-5). The
smears were examined using a Leitz Ortho-
plan microscope with a dark field condenser
and a HBO 200 light source fitted with a
UGI transmission filter and a K430 barrier
filter. Sera were considered to be positive
when more than 10% of the cells on the
smear showed cytoplasmic fluorescence.
The conjugate was absorbed twice with
acetone dried bovine liver powder (once at
37°C for 1 hour and once at 4°C overnight),
and then twice with packed M1M96 cells in a
similar way. before use. The conjugate was
diluted 1/15 and stored at -70 C until used.
A conjugate control was included in each
test but on no occasion did the conjugate
alone stain the melanoma cells. The con-
jugate was shown to have anti IgG and
anti IgM activity by immunodiffusion.
All sera giving definite cytoplasmic fluor-
escence with melanoma cells were also tested
against foetal and adult skin fibroblasts and
for antinuclear factor and smooth muscle
antibody. Any sera positive in any of
these tests were discarded.
RESULTS
Preliminary experiments comparing
fixation in cold acetone with fixation by
freezing in liquid nitrogen-isopentane
vielded similar results. Acetone fixation
was used in subsequent studies as cells
adhered better using this method. Fluo-
rescence was localized in the cytoplasm
and was normally diffuse in distribution.
The results obtained are summarized
in Table II. The cell lines varied greatly
in reactivity with the different groups
of sera, but this variation was not related
to either the pigmentation of the cells
or length of time in culture. The overall
incidence of fluorescence in tests with
sera from melanoma patients was 32%
whereas 17%0 of tests with sera from
control patients gave positive results
(P < 0-01, X2 test).
WVhen the immunofluorescence reac-
tions are tabulated in relation to the
degree of spread of the patients' tumour
TABLE II.-Summary of Immunofluorescence Reactions of Sera with
Melanoma Cell Lines
Melanoma cell lines
r -A' 5Total n
Sera 96 127 138 170 181 182 oftest
Normal (Caucasian) 3/29* 6/34 6/32 9/39 2/10 0/12 26/15
(10o) (180o) (190o) (230o) (200o) (170°
MNelanoma 14/49 23/48t 12/49 23/57 10,145 13,47 95, 299
(290o) (480o) (240o) (400o) (220o) (280o) (32 o
Normal (New GuIinea) 4/6 NYT 416 4'6 NT NT 12/18
(660o) (660o) (660o)
* Proportion of sera reacting.
t Significantly different (P < 0-01) from value for normal sera using Z2 test.
N-T Not tested.
10.
.ts
56
35t
3t
i (6600
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TABLE III.-Immunofluarescence Reactions ofSerafrom Patients
writh Melanoma
Cell lines
Tumour stage
Primary
Secondarv
" Ctured
Total no. of tests
* Proportion of sera reacting.
t Significantlv different (P < 0.01) from value for sera from primarv patients for using X2 test.
TABLE IV.-Immunofluorescence Reactions ofSera from Patients
with Primary Melanoma
Cell line
Depth of invassion (Clark, 1967)
Epidermis or upper dermis (Stage 1 and 2)
Lower dermis (Stage 3A and B)
* Proportion of sera reacting.
NT -Not tested.
K 5&
--, Total no.
96 127 138 170 181 182 of tests
0/5* NT 0/5 0/5 0/4 014 0/23
4/13 5/14 31/16 7/17 3/17 3/17 25/94
(Table III), it is apparent that sera
from patients with secondary melanoma
reacted more frequently than did sera
from patients with primary melanoma
(P < 0-01, X2 test). Sera from patients
considered to be cured " oftheir tumour
were found to react more frequently
than anv other group of sera.
Analysis of results of sera from
patients with primary melanoma which
had been staged for depth of invasion
according to Clark's classification (1967)
showed that no serum from anv patient
whose tumour was restricted to the
epidermis or upper dermis (stage 1 or 2)
reacted with any of the melanoma cell
lines (Table IV). However, sera from
patients whose tumour had invaded the
lower dermis were positive in up to
40%0 (7/17 against 1MM70) of cases.
The results mav be examined in a
different wav: of 22 sera from patients
with primary melanoma tested against
all 6 cell lines, 12 reacted with at least
one cell line (Table V). Similarly, of
16 sera from patients with secondary
melanoma tested against all cell lines,
TABLE V.--Cross-readivity of Sera from
Patients uith Melanoma against the Six
Jielanoma Cell Lines
Number of Primary Secondary
cell lines melanoma melanoma
reacted with sera reacting sera reacting
6
5
4
3
0
Total
Total positive
0
0
1
5
4
10
12 (5500)
1
2
2
0
6
3
16
13 (810Po)
13 reacted against at least one cell line
(Table V). However, the cell lines showed
very little cross-reactivity with sera from
melanoma patients. No primary serum
reacted with all 6 cell lines and only 3/22
sera reacted with 3 or more of the cell
lines. Sera from patients with secondary
melanoma showed more cross-reactivity
and 7/16 sera reacted with at least 3 of
the cell lines.
Six of the secondary melanoma sera
that were tested against all 6 melanomata
96
4/25*
(160o)
8/18
(440o )
2/6
(3300) 14/49
(290o)
127
6/20
(300o)
10/20
(500')
7/8
(870o)
23/48
(480o)
138
3/25
(120o)
7/19
(370)
2/5
(40Io)
12/49
(240o/)
170
10/27
(370)
8/22
(360o)
5/8
(629o)
23/57
(400)
181
3/23
(130/)
5/16
(310 )
2/6
(33O')
10/45
(220o)
182
3/24
(4'00
4l8
('500o) 13/47
(280o)
Total no.
of tests
29/144
(210o)
44/11Ot
(400O)
22/41t
(540,)
95/295
(3 0o)
r I
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reacted with one cell line only. Three
of these reacted with MM96, 2 with
MM127 and one with 1IM182. Of the
2 sera reacting with 4 cell lines, both
reacted with MM127, MM170 and MM182,
one also reacted with MM138 and the
other with iMM181. Sixteen secondary
sera were tested fully and there were a
total of36 reactions. IMl27 and MM182
were reacted 8 times, MM170 7 times,
MM96 6 times, 1Ml38 4 times and
MI181 3 times. These results are an
indication of the diversity of reactions
found.
DISCUSSION
This report describes a much lower
incidence of antibody to melanoma than
that found by most other authors using
immunofluorescent techniques. However,
the findings are in accordance with those
of Nairn et al. (1972), who have dealt in
detail with the possible reasons for
these discrepancies. Although early re-
ports tended to agree as to the proportion
of positive sera, the techniques and
methods of assessment differed. For in-
stance, Morton et al. (1968) described
both nuclear and cytoplasmic fluorescence
and used nuclear fluorescence as the
indicator of reactivity to 3 of their
melanomata whereas most other workers
have disregarded nuclear fluorescence.
The titre of the antibodv detected in the
serum has varied from 112 (Muna et
al., 1969) to 1/125 (Oettgen et al., 1968).
Other variations are seen in the methods
used to fix the cells and even the source
of the cells themselves.
It was decided to exclude any sera
containing antinuclear factor or smooth
muscle antibody, or reacting with adult
or foetal fibroblasts, from this study.
Most previous authors havenotadequately
excluded these factors and doubts have
been expressed as to the specificity of
the reactions described. It was realized
that by eliminating these sera, some sera
also showing anti-melanoma reactivity
might be excluded.
The results indicate that melanoma
cells in culture do contain an antigen
which reacts with sera from some melan-
oma patients. However, the cell lines
which are most reactive with melanoma
sera are also most reactive with normal
sera. Similar results are also seen in
the reports of Morton et al. (1968) and
Rohmsdahl and Cox (1970). M1orton et
al. reported that their most reactive
melanoma (measured by both nuclear
and cytoplasmic fluorescence) reacted
with 760/ of sera from melanoma patients
and 4300 of control sera. Similarlv,
Rohmsdahl found that a melanoma which
reacted with 89% of sera (measured by
cvtoplasmic fluorescence) from melanoma
patients also reacted with 430/ of normal
sera (Table VI). The high reactivitv of
TABLE VI.-Comparison of Results of Cell
Line showing M1ost Reaction with Control
Sera
Morton
et al.
(1968)
Sera
Melanoma
Normal
Rohmsdahl
et al.
(1970)
0O Positive
76 89
43 43
Whitehead
40
23
sera from normal New Guineans is also
difficult to explain, but is similar to a
previous report from Lewis et al. (1969)
who found that 21/25 normal negro sera
reacted with melanoma cells bv immuno-
fluorescence.
Hellstrom et al. (1973) have recently
reported that lymphocytes from healthy
North American negroes are cytotoxic
to cultured melanoma cells. They also
found that sera from these people are
able to " unblock " sera from patients
with melanoma. This suggests that there
is an antibody in the serum of normal
Negro people that can combine with
circulating antigen in the serum of a
patient with melanoma. These findings,
taken together, indicate the presence of
an antibody capable of reacting with
melanoma antigens in the blood ofnormal
dark skinned people and may explain
why melanomata are less common in
dark skinned people.
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The implication is that there is an
antigen in melanoma cells, either new
or unmasked, which reacts with sera
from some patients with melanoma. How-
ever, the fact that approximately 20%O
of normal sera also react with melanoma
cells argues against this new antigen
being melanoma specific.
The fact that the proportion of sera
positive can be described as 21%O (Table
III) or 55% (Table V) for sera from
primary melanomata and either 40/
(Table III) or 81 (Table V) for sera
from secondary melanomata, indicates
the dangers inherent in analysing data
such as these. No serum from a patient
with primarv melanoma reacted with
all 6 melanoma cell lines, and only 43%'
of sera from patients with secondarv
melanomata reacted with 3 or more of
the cell lines. These findings provide
no evidence for the presence of the
common antigen in melanoma cells sug-
gested previously by Morton et al. (1968)
and Lewis et al. (1969).
However, it is possible that the
tumour specific antigen was lost or
greatly diminished at an early stage of
the in uitro culture or that relatively
non-antigenic cell clones were selected
by the tissue culture conditions used.
I wish to thank Dr J. H. Little and
his colleagues of the Queensland Melan-
oma Project for obtaining the blood from
melanoma patients. I also wish to thank
Dr R. L. Doherty and Dr J. H. Pope for
their initial guidance and continuing
encouragement and advice and Miss
Marie Steen and ir P. Bvth for their able
technical assistance.
REFERENCES
CLARK, W. H. (1967) A Classification of 3alignant
MNelanoma in M1an Correlated with Histogenesis
and Biologic Behavior. Adr. Biol. Skin, 8, 621.
HELLSTROM, I., HELSTrROM, K. E., SJOGREN, H. 0.
& WARNER, G. A. (1973) Destruction ofCultivated
Melanoma Cells by Lymphocytes from Healthy
Black (North American) Donors. Int. J. Cancer,
11, 116.
LEwiS, M. G. (1967) Possible Immunological
Factors in Human Malignant Melanoma in
Uganda. Lancet, ii, 921.
LEWIS, M. G., IKON-OPISOV, R. L., NARN, R. C.,
P simrs, T. M., HAMnTTON FATITR Y, G., BODEN-
IA , D. C. & ATLEXAN-DER, P. (1969) Tumour-
specific Antibodies in Humnan Malignant Melan-
oma and their Relationship to the Extent of
Disease. Br. med. J., iii, 547.
MORTON. D. L., MA%LLMGREN-, R. A., HoLmfs, E. C.
& KETCHEM, A. S. (1968) Demonstration of
Antibodies against Human Malignant Melanoma
by Tmmunofluorescence. Surgery, St Louis, 64,
233.
MUNA, N. M., MARCUS, S. & SMART, C. (1969)
Detection by Immnunofluorescence of Anti-
bodies Specific for Human talignant Mfelanoma
Cells. Cancer, -.'V Y., 23, 88.
NAIR-, R. C., NIN-D, A. P. P., G-ii, E. P. G.,
DAVIES, D. J., LrLE, J. H., DAVIs, N. C. &
WiIrrEn.AI, R. H. (1972) Anti-tumour Reactivity
in Patients with Malignant Melanoma. Med. J.
Aust., 1, 397.
OETrGEN, H. F., AoKi, T., OLD, L. J., BOYSE,
E. A., DE HARVEN-, E. & 3MILS, G. M. (1968)
Suspension Culture of a Pigment Producing
Cell Line Derived from a Huiman Malignant
3Melanoma. J. natn. Cancer Inst., 41, 827.
ROHMSDAL, M. M. & COX, I. S. (1970) Human
Malignant Melanoma Antibodies Demonstrated
by Immunofluoreseence. Archas Surg., 100, 491.
WE=rEA, R. H. & LrrE, J. H. (1972) Tiw
Culture Studies in Malignant Mdeanoma. In
Proc. VU1th. Internat. Pigment Cell Congr.
Basle: Karger A.G. In the press.